Carcinoma, Renal Cell: all 1,992 studies

Page 5 of 20. Open to participants first (387), then studies with results posted, then the rest; newest registration first within each.

• Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Metastatic Renal Cell CarcinomaTerminatedNCT04831138Not applicableResults posted
• A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has SpreadActive, not recruitingNCT04810078Phase 3Results posted
• Survey of Cabozantinib Used To Treat People With Renal Cell CarcinomaCompletedNCT04804813Results posted
• Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)CompletedNCT04704219Phase 2Results posted
• To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell CarcinomaCompletedNCT04682587Results posted
• Study of INCB086550 in Select Solid TumorsTerminatedNCT04629339Phase 2Results posted
• Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid TumorsTerminatedNCT04628780Phase 1Results posted
• ABEMA Alone or in COMBO With MK-6482CompletedNCT04627064Phase 1Results posted
• Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic RadiosurgeryTerminatedNCT04588246Phase 3Results posted
• Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVActive, not recruitingNCT04514484Phase 1Results posted
• Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)CompletedNCT04508725Not applicableResults posted
• Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell CarcinomaTerminatedNCT04495894Phase 2Results posted
• A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)CompletedNCT04489771Phase 2Results posted
• Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell CarcinomaActive, not recruitingNCT04393350Phase 2Results posted
• Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCCCompletedNCT04375150Results posted
• Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing SurgeryTerminatedNCT04370509Phase 2Results posted
• Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid TumorsCompletedNCT04349267Phase 1/2Results posted
• A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor TreatmentTerminatedNCT04338269Phase 3Results posted
• Talazoparib and Axitinib for People With Previously Treated Advanced Kidney CancerCompletedNCT04337970Phase 1/2Results posted
• Retrospective Study on Referral Patterns for High Risk Patients Post NephrectomyCompletedNCT04309617Results posted
• PET/MR Characterization of Renal Cell CarcinomasTerminatedNCT04271254Not applicableResults posted
• Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor SitesStatus unknownNCT04267575Not applicableResults posted
• Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)TerminatedNCT04267120Phase 2Results posted
• Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid TumorsTerminatedNCT04234113Phase 1Results posted
• A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)Active, not recruitingNCT04195750Phase 3Results posted
• Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) TreatmentsCompletedNCT04175262Results posted
• Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal CarcinomaTerminatedNCT04150562Phase 2Results posted
• A Retrospective Medical Record Review of First-Line Sunitinib Administration Schedules and Outcomes Among Patients With mRCC in Latin America (LA)CompletedNCT04115189Results posted
• A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell CarcinomaTerminatedNCT04088500Phase 2Results posted
• Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line SunitinibCompletedNCT04076787Results posted
• Talazoparib and Avelumab in Participants With Metastatic Renal Cell CarcinomaCompletedNCT04068831Phase 2Results posted
• Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.CompletedNCT04033991Results posted
• Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney CancerActive, not recruitingNCT04022343Phase 2Results posted
• Contrast-Enhanced Ultrasound for Kidney Cancer Subtyping and StagingCompletedNCT04021238Phase 2Results posted
• High Dose IL-2 in Combination With Anti-PD-1TerminatedNCT03991130Phase 2Results posted
• Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in OncologyCompletedNCT03948724Not applicableResults posted
• Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint InhibitorsCompletedNCT03945773Phase 2Results posted
• Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell CarcinomaActive, not recruitingNCT03937219Phase 3Results posted
• REGISTRY OF COMPLETE RESPONSES TO SUNITINIB IN SPANISH PATIENTS WITH METASTATIC RENAL CELL CARCINOMACompletedNCT03916458Results posted
• Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid TumorsTerminatedNCT03875313Phase 1/2Results posted
• 89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON StudyCompletedNCT03849118Phase 3Results posted
• A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced MalignanciesTerminatedNCT03829501Phase 1/2Results posted
• Correlation of Renal Mass Pathologic Grade and Contrast Enhanced Ultrasound (CEUS)TerminatedNCT03821376Phase 4Results posted
• A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)TerminatedNCT03729245Phase 3Results posted
• Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular DiseaseTerminatedNCT03709771Results posted
• PF-06952229 Treatment in Adult Patients With Advanced Solid TumorsTerminatedNCT03685591Phase 1Results posted
• Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell CarcinomaCompletedNCT03680521Phase 2Results posted
• A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)CompletedNCT03679767Phase 2Results posted
• Mobile Intervention - Physical Activity in Cancer TreatmentTerminatedNCT03671304Not applicableResults posted
• Study of ADCT-301 in Patients With Selected Advanced Solid TumorsTerminatedNCT03621982Phase 1Results posted
• A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)Active, not recruitingNCT03595124Phase 2Results posted
• GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid TumorsTerminatedNCT03576131Phase 1/2Results posted
• Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell CarcinomaTerminatedNCT03562507Phase 2Results posted
• Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell CarcinomaTerminatedNCT03552380Phase 2Results posted
• "Retrospective Study to Identify Clinical Factors Related to a High Benefit of Axitinib in mRCC"CompletedNCT03538717Results posted
• APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell CarcinomaCompletedNCT03502330Phase 1Results posted
• Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer With Venous InvasionCompletedNCT03494816Phase 2Results posted
• UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint BlockadeActive, not recruitingNCT03474497Phase 1/2Results posted
• REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor MalignanciesTerminatedNCT03435640Phase 1/2Results posted
• CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell CarcinomaCompletedNCT03428217Phase 2Results posted
• Functional Microscale Organotypic Assays to Predict Patient Response to Anti-Angiogenesis TherapiesTerminatedNCT03387514Phase 2Results posted
• A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell CarcinomaCompletedNCT03339219Phase 2Results posted
• Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by SurgeryTerminatedNCT03334409Phase 2Results posted
• Using Virtual Reality (VR) Models for Preoperative PlanningCompletedNCT03334344Not applicableResults posted
• A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid TumorsTerminatedNCT03311334Phase 1/2Results posted
• A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell CarcinomaCompletedNCT03294083Phase 1/2Results posted
• Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary CarcinomaTerminatedNCT03274258Phase 2Results posted
• Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)CompletedNCT03260894Phase 3Results posted
• Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney CancerTerminatedNCT03260504Phase 1Results posted
• Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or LymphomaCompletedNCT03229278Phase 1Results posted
• A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin LymphomaTerminatedNCT03207867Phase 2Results posted
• A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)CompletedNCT03207347Phase 2Results posted
• Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor TreatmentCompletedNCT03200717Phase 2Results posted
• Diagnostic Imaging for Clear Cell Renal Cell CarcinomaTerminatedNCT03185182Phase 2Results posted
• Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell CarcinomaCompletedNCT03173560Phase 2Results posted
• A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney CancerTerminatedNCT03165721Phase 2Results posted
• CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)CompletedNCT03163667Phase 2Results posted
• Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With CancerCompletedNCT03154190Not applicableResults posted
• Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell CarcinomaCompletedNCT03149822Phase 1/2Results posted
• Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)CompletedNCT03142334Phase 3Results posted
• A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell CarcinomaCompletedNCT03141177Phase 3Results posted
• Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy.TerminatedNCT03140176Results posted
• M8891 First in Human in Solid TumorsTerminatedNCT03138538Phase 1Results posted
• A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a KidneyCompletedNCT03138512Phase 3Results posted
• Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic MalignanciesCompletedNCT03126110Phase 1/2Results posted
• A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary CancersTerminatedNCT03115801Phase 2Results posted
• Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise TestingCompletedNCT03109015Phase 2Results posted
• MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003)CompletedNCT03108066Phase 2Results posted
• Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell CarcinomaCompletedNCT03097328Phase 2Results posted
• Savolitinib vs. Sunitinib in MET-driven PRCC.Active, not recruitingNCT03091192Phase 3Results posted
• Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized TrialActive, not recruitingNCT03075072Not applicableResults posted
• SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer PatientsCompletedNCT03065179Phase 2Results posted
• Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing NephrectomyActive, not recruitingNCT03055013Phase 3Results posted
• Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney CancerTerminatedNCT03050060Phase 2Results posted
• An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell CarcinomaCompletedNCT03029780Phase 2Results posted
• A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following NephrectomyTerminatedNCT03024996Phase 3Results posted
• Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell CarcinomaTerminatedNCT03024437Phase 1/2Results posted
• Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney CancerCompletedNCT03015740Phase 1/2Results posted
• A Study to Test Combination Treatments in People With Advanced Renal Cell CarcinomaCompletedNCT02996110Phase 2Results posted
• Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell CancerCompletedNCT02989714Phase 1/2Results posted

← Carcinoma, Renal Cell overview